Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series.
Lijia ZhangLarry BorishAnna SmithLindsay SomervilleDana AlbonPublished in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2020)
Mepolizumab appears to have a positive effect on clinical course in patients with CF presenting with a type 2 phenotype characterized by allergic sensitization and hyper-eosinophilia.